Notably, this FASN inhibition also contributed to decreased cell proliferation and increased apoptosis, pointing toward its potential as a therapeutic target to modulate endometrial carcinoma progression and hormone-dependent signaling pathways [62]. This evidence concerns the gene FASN and endometrial carcinoma.